Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705646 | 0.90 | SIRT2 (0.49) | PARP10HTTLMNAMRGPRX4 | |
| SCHEMBL2704584 | 0.88 | MRGPRX4 (0.48) | HTTLMNAMRGPRX4 | |
| SCHEMBL30719659 | 0.88 | PTGER1 (0.52) | KDM1ANPC1PTGER1MRGPRX4S1PR5 | |
| SCHEMBL19285679 | 0.88 | PTGER1 (0.52) | KDM1ANPC1PTGER1MRGPRX4S1PR5 | |
| SCHEMBL2707206 | 0.86 | FFAR1 (0.51) | PARP10HTTLMNAMRGPRX4 | |
| SCHEMBL202627 | 0.86 | MAOB (0.56) | PARP10HTTLMNAMRGPRX4 | |
| SCHEMBL28316118 | 0.85 | KDM1A (0.50) | KDM1ANPC1PTGER1LMNAMRGPRX4 | |
| SCHEMBL2707335 | 0.85 | MRGPRX4 (0.54) | MRGPRX4 | |
| SCHEMBL2705980 | 0.84 | LMNA (0.49) | NPC1PARP10HTTLMNAMRGPRX4 | |
| SCHEMBL202507 | 0.84 | MRGPRX4 (0.53) | PARP10HTTLMNAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20210139508-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| CN-110078680-B | Isoxazoline benzamide compound and preparation method and application thereof | 山东大学 | 2021-02-19 | — | — | CN | disclosed |
| US-10774093-B2 | Synthetic processes and synthetic intermediates | TAXIS PHARMACEUTICALS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200055870-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| CN-110078680-A | Isoxazoline benzamide compound and its preparation method and application | 山东大学 | 2019-08-02 | — | — | CN | disclosed |
| US-20190048024-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048024-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| CN-109195957-A | Synthetic Methods and Intermediates | 塔克西斯医药股份有限公司 | 2019-01-11 | — | — | CN | disclosed |
| EP-3419967-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | Taxis Pharmaceuticals, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017147316-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147316-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139508-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | KDM1A 4278/4885NPC1 4438/4885PARP10 618/4885 |
| US-20190048024-A1 | SYNTHETIC PROCESSES AND INTERMEDIATES | CYP11B1, CYP11B2, REN | KDM1A 4184/4885NPC1 1023/4885PARP10 2516/4885 |
| US-20200055870-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | KDM1A 4278/4885NPC1 4438/4885PARP10 618/4885 |
| US-10774093-B2 | Synthetic processes and synthetic intermediates | TXN, TBXAS1, TXK | KDM1A 4278/4885NPC1 4438/4885PARP10 618/4885 |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | KDM1A 4278/4885NPC1 4438/4885PARP10 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.